ALX Oncology   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Burlingame CA United States (2015)

Organization Overview

First Clinical Trial
2017
NCT03013218
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ALX Oncology | ALX Oncology Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Preleukemia (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 15